BSP Pharmaceuticals

Latina, Italy

Profile last updated: 2026-06-29

Biologics mRNA

No confirmed program data — ClinicalTrials.gov verification pending · Last scored 2026-09-07

70.5

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ✓ EMA GMP (14) ○ MHRA GMP

Quick Facts: BSP Pharmaceuticals

Signal Score: 70.5/100 (as of 2026-09-07)
Quality Compliance: 83.6/100
Headquarters: Latina, Italy
Modalities: Biologics, mRNA
Active Programs: Data pending
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About BSP Pharmaceuticals

Pure-play CDMO.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.

Quality Compliance

FDA InspectionsNo US records on file

EMA GMP Certificates14 on record

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesBiologics, mRNA

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Capacity

Profile-based capacity assessment

Attribution not established (7)

These records are excluded from this company’s established evidence because their attribution is unresolved. This describes an evidence-linking limitation, not an assessment of the underlying regulatory findings.

Source	Establishment named by the regulator	Location	Identifier
FDA inspection	Actavis Laboratories FL, Inc. dba Teva Pharmaceuticals	Davie, Florida	FDA/FEI=3003194604
FDA inspection	Apozeal Pharmaceuticals Inc.	Levittown, Pennsylvania	FDA/FEI=3004536846
FDA inspection	Haisco-USA Pharmaceuticals, Inc.	Bridgewater, New Jersey	FDA/FEI=3039464114
FDA inspection	Avadel CNS Pharmaceuticals LLC	Chesterfield, Missouri	FDA/FEI=3012841301
FDA inspection	Boehringer Ingelheim Pharmaceuticals, Inc.	Ridgefield, Connecticut	FDA/FEI=1219205
FDA inspection	Beutlich Pharmaceuticals LLC	Bunnell, Florida	FDA/FEI=1413399
FDA inspection	Surmasis Pharmaceutical, LLC	Des Moines, Iowa	FDA/FEI=3011596846

Source records retained verbatim · attribution not established

BSP Pharmaceuticals EMA GMP Compliance 14 certificates

2025-02

2024-10

2022-05

2021-11

2019-11

Compliant Non-Compliant

Certificate	Site	Country	Inspection Date	Status
IT/42/H/2025	Bsp Pharmaceuticals S.p.A.	Italy	2025-02-21	COMPLIANT
IT-API/12/H/2025	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/25/H/2025	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/83/H/2025	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/10/H/2026	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/45/H/2026	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/75/H/2026	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/87/H/2026	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/117/H/2026	Bsp Pharmaceuticals S.p.A.	Italy	2024-10-11	COMPLIANT
IT-API/7/H/2023	Bsp Pharmaceuticals S.p.A.	Italy	2022-05-27	COMPLIANT
IT-API/72/H/2024	Bsp Pharmaceuticals S.p.A.	Italy	2022-05-27	COMPLIANT
IT-API/79/H/2022	Bsp Pharmaceuticals S.p.A.	Italy	2021-11-12	COMPLIANT
IT-API/107/H/2021	BSP PHARMACEUTICALS S.P.A.	Italy	2019-11-22	COMPLIANT
IT-API/54/H/2021	BSP PHARMACEUTICALS S.P.A.	Italy	2019-11-22	COMPLIANT